Streamlining drug synthesis

Joel M. Hawkins ()
Additional contact information
Joel M. Hawkins: Joel M. Hawkins is in Chemical Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, USA.

Nature, 2015, vol. 520, issue 7547, 302-303

Abstract: Drug manufacture can benefit from flow synthesis, in which raw materials are fed into a sequence of reactors, producing the drug as a continuous output. A flow strategy that capitalizes on solid catalysts has now been realized. See Letter p.329

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/520302a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:520:y:2015:i:7547:d:10.1038_520302a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/520302a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().